The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 16, Issue 5, 2016, Pages 639-650

  Fadare, Joseph O ^a   Adeoti, Adekunle O ^a   Desalu, Olufemi O ^b   Enwere, Okezie O ^c   Makusidi, Aliyu M ^d   Ogunleye, Olayinka ^e,f   Sunmonu, Taofiki A ^g   Truter, Ilse ^h   Akunne, Onyinye O ⁱ   Godman, Brian ^j,k  

^a EKITI STATE UNIVERSITY   (Nigeria)

^b UNIVERSITY OF ILORIN   (Nigeria)

^c IMO STATE UNIVERSITY   (Nigeria)

^d USMANU DANFODIYO UNIVERSITY   (Nigeria)

^e LAGOS STATE UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^f LAGOS STATE UNIVERSITY   (Nigeria)

^g FEDERAL MEDICAL CENTER   (Nigeria)

^h NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

ⁱ UNIVERSITY OF IBADAN   (Nigeria)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k UNIVERSITY OF STRATHCLYDE   (United Kingdom)

more..

Author keywords

generic substitution; Generics; Nigeria; physicians knowledge and attitudes; prescribing

Indexed keywords

DOCTOR PATIENT RELATION; HEALTH CARE FACILITY; HUMAN; HUMAN EXPERIMENT; MALE; NIGERIA; PERCEPTION; PHARMACIST; PRESCRIPTION; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; ATTITUDE TO HEALTH; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DRUG SUBSTITUTION; FEMALE; HEALTH PERSONNEL ATTITUDE; ORGANIZATION AND MANAGEMENT; PHYSICIAN; PROFESSIONAL STANDARD; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

GENERIC DRUG;

ATTITUDE OF HEALTH PERSONNEL; CROSS-SECTIONAL STUDIES; DRUG SUBSTITUTION; DRUGS, GENERIC; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; NIGERIA; PERCEPTION; PHARMACISTS; PHYSICIANS; PRACTICE PATTERNS, PHYSICIANS'; PROFESSIONAL ROLE; SURVEYS AND QUESTIONNAIRES;

EID: 84951871852     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2016.1120673     Document Type: Article

References (103)

1. M.A.Hassali, A.A.Alrasheedy, A.McLachlan, et al. The experiences of implementing generic medicine policy in eight countries:A review and recommendations for a successful promotion of generic medicine use. SAUDI PHARM J Journal. 2014;22(6):491–503.
2. C.Baumgartel Myths, questions, facts about generic drugs in the EU. Gabi Journal. 2012;1(1):34–38.
3. P.Dylst, A.Vulto, B.Godman, et al. Generic medicines:solutions for a sustainable drug market? Appl Health Econ Health Policy. 2013;11(5):437–443.
4. S.Vogler. The impact of pharmaceutical pricing and reimbursement policies on generics uptake:implementation of policy options on generics in 29 European countries–an overview. GaBI Journal. 2012;1(2):93–100.
5. A.Cameron, A.K.Mantel-Teeuwisse, H.G.Leufkens, et al. Switching from originator brand medicines to generic equivalents in selected developing countries:how much could be saved? Value Health. 2012;15(5):664–673.
6. U.S. Food and Drug Administration [Internet]. Abbreviated New Drug Application (ANDA):Generics. 2014 [cited 2015 Feb 2]. Available from:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/
7. A.S.Kesselheim, A.S.Misono, J.L.Lee, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease:a systematic review and meta-analysis. JAMA:Journal Am Med Assoc. 2008;300(21):2514–2526.
8. A.S.Kesselheim, M.R.Stedman, E.J.Bubrick, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs:a systematic review and meta-analysis. Drugs. 2010;70(5):605–621.
9. G.Corrao, D.Soranna, A.Arfe, et al. Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. Eur J Intern Med. 2014;25(8):745–750.
10. G.Corrao, D.Soranna, L.Merlino, et al. Similarity between generic and brand-name antihypertensive drugs for primary prevention of cardiovascular disease:evidence from a large population-based study. Eur J Clin Invest. 2014;44(10):933–939.
11. G.Corrao, D.Soranna, C.La Vecchia, et al. Medication persistence and the use of generic and brand-name blood pressure-lowering agents. J Hypertens. 2014;32(5):1146–53; discussion 53.
12. M.Veronin. Should we have concerns with generic versus brand antimicrobial drugs? A review of issues. JPHSR. 2011;2:135–150.
13. C.Paton. Generic clozapine:outcomes after switching formulations. Br J Psychiatry. 2006;189:184–185.
14. OECD. OECD, Health at a Glance 2011:OECD Indicators [Internet]. [cited 2015 Aug 15]. Pharmaceutical expenditure OECD Publishing. 2011. Available from:http://www.oecd.org/els/health-systems/49105858.pdf
15. A.Cameron, M.Ewen, D.Ross-Degnan, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries:a secondary analysis. Lancet. 2009;373(9659):240–249.
16. W.Kaplan, V.Wirtz, A.Mantel-Teeuwisse, et al. Priority Medicines for Europe and the World 2013 Update Report [Internet]. 2013 [cited 2015 Aug 15]. Available from:http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf?ua=1.
17. B.Godman, B.Wettermark, M.Van Woerkom, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures:findings and future implications. Front Pharmacol. 2014;5:106.
18. P.Dylst, A.Vulto, S.Simoens. Demand-side policies to encourage the use of generic medicines:an overview. Expert Rev Pharmacoecon Outcomes Res. 2013;13(1):59–72.
19. B.Godman, M.Abuelkhair, A.Vitry, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GaBI. 2012;1(2):21–35.
20. S.Vogler, N.Zimmermann. How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria. GaBI Journal. 2013;2(2):65–75.
21. E.Poluzzi, G.Veronese, C.Piccinni, et al. Switching among equivalents in chronic cardiovascular therapies:‘Real World’ Data from Italy. Basic Clin Pharmacol Toxicol. 2015. [Epub ahead of print].
22. C.Sermet, V.Andrieu, B.Godman, et al. Ongoing pharmaceutical reforms in France:implications for key stakeholder groups. Appl Health Econ Health Policy. 2010;8(1):7–24.
23. K.Garuoliene, B.Godman, J.Gulbinovic, et al. European countries with small populations can obtain low prices for drugs:Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11(3):343–349.
24. M.G.Duerden, D.A.Hughes. Generic and therapeutic substitutions in the UK:are they a good thing? Br J Clin Pharmacol. 2010;70(3):335–341.
25. B.Godman, I.Bishop, A.E.Finlayson, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):469–482.
26. K.A.Andersson, M.G.Petzold, P.Allebeck, et al. Influence of mandatory generic substitution on pharmaceutical sales patterns:a national study over five years. BMC Health Serv Res. 2008;8:50.
27. T.Moe-Byrne, D.Chambers, M.Harden, et al. Behaviour change interventions to promote prescribing of generic drugs:a rapid evidence synthesis and systematic review. BMJ Open. 2014;4(5):e004623.
28. I.Kjoenniksen, M.Lindbaek, A.G.Granas. Patients’ attitudes towards and experiences of generic drug substitution in Norway. Pharmacy World Science:PWS. 2006;28(5):284–289.
29. B.Godman, I.Bishop, S.M.Campbell, et al. Quality and efficiency of statin prescribing across countries with a special focus on South Africa; findings and future implications. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):323–330.
30. Y.Bao, A.M.Ryan, H.Shao, et al. Generic initiation and antidepressant therapy adherence under Medicare Part D. Am J Manag Care. 2013;19(12):989–998.
31. B.A.Briesacher, S.E.Andrade, H.Fouayzi, et al. Medication adherence and use of generic drug therapies. Am J Manag Care. 2009;15(7):450–456.
32. S.Sakshaug, K.Furu, O.Karlstad, et al. Switching statins in Norway after new reimbursement policy:a nationwide prescription study. Br J Clin Pharmacol. 2007;64(4):476–481.
33. J.E.Martikainen, L.K.Saastamoinen, M.J.Korhonen, et al. Impact of restricted reimbursement on the use of statins in Finland:a register-based study. Medical Care. 2010;48(9):761–766.
34. J.Moon, B.Godman, M.Petzold, et al. Different initiatives across Europe to enhance losartan utilisation post generics:impact and implications. Front Pharmacol. 2014;5(Article 219):1–10.
35. G.Heinze, M.Hronsky, B.Reichardt, et al. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria:a nationwide cohort study. Appl Health Econ Health Policy. 2015;13(2):193–205.
36. J.Usher-Smith, T.Ramsbottom, H.Pearmain, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting:2 years on. Int J Clin Pract. 2008;62(3):480–484.
37. M.Bennie, B.Godman, I.Bishop, et al. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):125–130.
38. A.Martin, B.Godman, J.Miranda, et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK:findings and implications. J Comp Eff Res. 2014;3(1):41–51.
39. C.Norman, R.Zarrinkoub, J.Hasselstrom, et al. Potential savings without compromising the quality of care. Int J Clin Pract. 2009;63(9):1320–1326.
40. D.R.King, P.Kanavos. Encouraging the use of generic medicines:implications for transition economies. Croat Med J. 2002;43(4):462–469.
41. V.Paris. Pharmaceutical regulation in France 1980–2003. Int J Health Plann Manage. 2005;20(4):307–328.
42. B.Godman, W.Shrank, M.Andersen, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization:changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):707–722.
43. G.N.Chua, M.A.Hassali, A.A.Shafie, et al. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia. Health Policy. 2010;95(2–3):229–235.
44. M.Theodorou, V.Tsiantou, A.Pavlakis, et al. Factors influencing prescribing behaviour of physicians in Greece and Cyprus:results from a questionnaire based survey. BMC Health Serv Res. 2009;9:150.
45. A.S.Al-Jazairi, S.Bhareth, I.S.Eqtefan, et al. Brand and generic medications:are they interchangeable? Ann Saudi Med. 2008;28(1):33–41.
46. Z.U.Babar, P.Grover, J.Stewart, et al. Evaluating pharmacists’ views, knowledge, and perception regarding generic medicines in New Zealand. Res Social Adm Pharm. 2011;7(3):294–305.
47. P.Dylst, A.Vulto, S.Simoens. Analysis of French generic medicines retail market:why the use of generic medicines is limited. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):795–803.
48. Editorial. Generic bashing:effective but illegal. Prescrire Int. 2013;22(144):307.
49. C.Baumgärtel, B.Godman, R.Malmström, et al. What lessons can be learned from the launch of generic clopidogrel? GaBI Journal. 2012;1(2):58–68.
50. R.Kumar, M.A.Hassali, F.Saleem, et al. Knowledge and perceptions of physicians from private medical centres towards generic medicines:a nationwide survey from Malaysia. J Pharm Policy Pract. 2015;8(1):11.
51. R.E.Ferner, W.Lenney, J.F.Marriott. Controversy over generic substitution. BMJ (Clinical Research Ed). 2010;340:c2548.
52. MHRA. Antiepileptic drugs:new advice on switching between different manufacturers’ products for a particular drug [Internet]. 2013 [cited 2015 Aug 20]. Available from:http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON3367162013.
53. B.Godman, C.Baumgartel. Are generic immunosuppressants safe and effective? BMJ. 2015;350:h3248.
54. V.Fabiano, C.Mameli, D.Cattaneo, et al. Perceptions and patterns of use of generic drugs among Italian family pediatricians:first round results of a web survey. Health Policy. 2012;104(3):247–252.
55. E.T.Adebayo, N.A.Hussain. Pattern of prescription drug use in Nigerian army hospitals. Ann Afr Med. 2010;9(3):152–158.
56. O.O.Enwere, C.O.Falade, B.L.Salako. Drug prescribing pattern at the medical outpatient clinic of a tertiary hospital in southwestern Nigeria. Pharmacoepidemiol Drug Saf. 2007;16(11):1244–1249.
57. I.Tamuno, J.O.Fadare. Drug prescription pattern in a Nigerian tertiary hospital. Trop J Pharm Res. 2012;11(1):146–152.
58. Federal Ministry of Health. Standard treatment guidelines [Internet]. Abuja:Federal Ministry of Health of Nigeria (collaboration with WHO, EC, DFID); 2008. Available from:http://apps.who.int/medicinedocs/documents/s17035e/s17035e.pdf
59. National Agency for Food and Drug Administration and Control (NAFDAC). Guidelines for registration of drugs and related products manufactured In Nigeria. Abuja:National Agency for Food and Drug Administration and Control of Nigeria; 2014.
60. Health Expenditure, total (% of GDP) [Internet]. 2015. [cited 2015 Mar 7]. Available from:www.worldbank.org.
61. M.N.Onah, V.Govender. Out-of-Pocket payments, health care access and utilisation in South-Eastern Nigeria:A gender perspective. PLoS One. 2014;9(4):e93887.
62. O.Onwujekwe, K.Hanson, H.Ichoku, et al. Financing incidence analysis of household out-of-pocket spending for healthcare:getting more health for money in Nigeria? Int J Health Plann Manage. 2014;29(2):e174–85.
63. O.Ewelukwa, C.Onoka, O.Onwujekwe. Viewing health expenditures, payment and coping mechanisms with an equity lens in Nigeria. BMC Health Serv Res. 2013;13:87.
64. I.A.Odeyemi, J.Nixon. Assessing equity in health care through the national health insurance schemes of Nigeria and Ghana:a review-based comparative analysis. Int J Equity Health. 2013;12:9.
65. C.Ezenduka, V.Ubochi, B.Ogbonna. The utilization pattern and costs analysis of psychotropic drugs at a neuropsychiatric hospital in Nigeria. Br J Pharm Res. 2014;4(3):325–337.
66. C.Barbui, V.Conti. Adherence to generic v. brand antidepressant treatment and the key role of health system factors. Epidemiol Psychiatr Sci. 2014;24(1):23–26.
67. W.H.Shrank, T.Hoang, S.L.Ettner, et al. The implications of choice:prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332–337.
68. O.E.Onwujekwe, B.S.Uzochukwu, E.N.Obikeze, et al. Investigating determinants of out-of-pocket spending and strategies for coping with payments for healthcare in southeast Nigeria. BMC Health Serv Res. 2010;10:67.
69. S.Q.Jamshed, M.I.Ibrahim, M.A.Hassali, et al. Perception and attitude of general practitioners regarding generic medicines in Karachi, Pakistan:A questionnaire based study. South Med Rev. 2012;5(1):22–30.
70. B.Godman, W.Shrank, M.Andersen, et al. Policies to enhance prescribing efficiency in europe:findings and future implications. Front Pharmacol. 2010;1:141.
71. B.Godman, M.Petzold, K.Bennett, et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources?:findings from across Europe and their implications. BMC Medicine. 2014;12(1):98.
72. L.Voncina, T.Strizrep, B.Godman, et al. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe:implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):469–479.
73. Raosoft Inc. Raosoft Sample Size Calculator Seattle, USA2004 [Internet]. 2014 [cited 2015 May 15]. Available from:http://www.raosoft.com/samplesize.html.
74. G.Labiris, M.Fanariotis, C.Kastanioti, et al. Greek physicians’ perceptions on generic drugs in the era of austerity. Scientifica (Cairo). 2015;2015:251792.
75. C.Key, D.Layton, S.A.Shakir. Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety. Pharmacoepidemiol Drug Saf. 2002;11(2):143–148.
76. S.Fischer, G.Miccinesi, R.Hornung, et al. Responders and non-responders in a study on medical end-of-life decisions in Denmark, the Netherlands, Sweden and Switzerland. Soz Praventivmed. 2006;51(1):24–33.
77. A.Awaisu, N.Kheir, M.I.Ibrahim, et al. Knowledge, attitudes, and practices of community pharmacists on generic medicines in Qatar. Int J Clin Pharm. 2014;36(2):394–404.
78. M.A.Hassali, Z.Y.Wong, A.A.Alrasheedy, et al. Perspectives of physicians practicing in low and middle income countries towards generic medicines:a narrative review. Health Policy. 2014;117(3):297–310.
79. S.Zaoui, F.Hakkou, H.Filali. Generic drugs in morocco:survey of physicians. Therapie. 2011;66(6):499–506.
80. G.Borgheini. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003;25(6):1578–1592.
81. P.Le Corre. Bioequivalence and generics of index drugs with narrow therapeutic margins. Presse Med. 2010;39(2):169–176.
82. A.Holbrook, J.Lexchin, E.Pullenayegum, et al. What do Canadians think about physician-pharmaceutical industry interactions? Health Policy. 2013;112(3):255–263.
83. S.Y.Yu, B.M.Yang, J.H.Kim. New anti-rebate legislation in South Korea. Appl Health Econ Health Policy. 2013;11(4):311–318.
84. B.Roehr. Drug companies will have to report all payments to US doctors from March 2014. Bmj. 2013;346:f826.
85. C.Davis, J.Abraham. Is there a cure for corporate crime in the drug industry? BMJ. 2013;346:f755.
86. L.Voncina, T.Strizrep. Croatia:2009/2010 pharmaceutical pricing and reimbursement reform. Eurohealth. 2011;16(4):20–22.
87. G.K.Spurling, P.R.Mansfield, B.D.Montgomery, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing:a systematic review. PLoS Med. 2010;7(10):e1000352.
88. M.Civaner. Sale strategies of pharmaceutical companies in a “pharmerging” country:the problems will not improve if the gaps remain. Health Policy. 2012;106(3):225–232.
89. J.Kersnik, J.Peklar. Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies. J Clin Pharm Ther. 2006;31(6):577–583.
90. H.Riaz, B.Godman, S.Hussain, et al. Prescribing of bisphosphonates and antibiotics in Pakistan:challenges and opportunities for the future. J Pharm Health Serv Res. 2015;6:111–121.
91. H.Z.Toklu, G.A.Dulger, S.Hidiroglu, et al. Knowledge and attitudes of the pharmacists, prescribers and patients towards generic drug use in Istanbul - Turkey. Pharm Pract (Granada). 2012;10(4):199–206.
92. P.N.Newton, A.A.Amin, C.Bird, et al. The primacy of public health considerations in defining poor quality medicines. PLoS Med. 2011;8(12):e1001139.
93. A.Johnston, D.W.Holt. Substandard drugs:a potential crisis for public health. Br J Clin Pharmacol. 2014;78(2):218–243.
94. E.F.T Hoen, H.V.Hogerzeil, J.D.Quick, et al. A quiet revolution in global public health:the World Health Organization’s Prequalification of Medicines Programme. J Public Health Policy. 2014;35(2):137–161.
95. Y.R.Wang. The Chinese pharmaceutical market at the crossroads:pro-competition solutions to improve access, quality and affordability. Appl Health Econ Health Policy. 2005;4(3):147–151.
96. O.O.Oyetunde, B.A.Aina, F.Tayo. Impact of generic substitution practice on care of diabetic patients. Int J Clin Pharm. 2014;36(3):623–629.
97. S.C.Basak, D.Sathyanarayana. Exploring knowledge and perceptions of generic medicines among drug retailers and community pharmacists. Indian J Pharm Sci. 2012;74(6):571–575.
98. K.Andersson, C.Sonesson, M.Petzold, et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 2005;14(5):341–348.
99. K.Andersson, T.Jorgensen, A.Carlsten. Physicians’ opinions and experiences of the pharmaceutical benefits reform. Scand J Public Health. 2006;34(6):654–659.
100. Nigerian Medical Association [Internet]. 2014 [cited 2015 Aug 1]. Available from:http://nationalnma.org/.
101. A.Cameron, M.Ewen, D.Ross-Degnan, et al. Medicine prices, availability, and affordability in 36 developing and middle-income countries:a secondary analysis. The Lancet. 2009;373(9659):240–249. DOI:10.1016/S0140-6736(08)61762-6
102. M.Woerkom, H.Piepenbrink, B.Godman, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands:influence and future implications. J Comp Eff Res. 2012;1(6):527–538.
103. B.Godman, B.Wettermark, M.Hoffmann, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden:global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65–83.